cancel
Showing results for 
Search instead for 
Did you mean: 
tfujimoto
Contributor

GSK369796 (Phase-I), Antimalarial for the 21st Century

The rational drug design for antimalarial was reported. Using the 4-aminoquinoline amodiaquine as a template, they designed analogues that are highly effective against chloroquine-resistant parasites and against parasites obtained from clinical failures after treatment with amodiaquine. At first, they exchanged hydroxyl and diethylaminomethyl of amodiaquine to avoid quinoneimine bioactivation. The resulting compound 3 was subject to unacceptably high first pass metabolism to dealkylated metabolites in four animal species. After optimization of compound 3, N-tert-butyl isoquine (GSK369796) was discovered.

http://pubs.acs.org/doi/pdf/10.1021/jm8012618



0 Kudos
tfujimoto
Contributor

Human Metabolites in Safety Testing (MIST) Issue

Recent changes in the Food and Drug Administration’s guidance on metabolites in safety testing (MIST) have had a major impact on the approach to toxicity testing of drug metabolites. These changes have required new strategies for the evaluation of metabolites at the early stages of drug development. In this issue, toxicologists from industry and academia share their experiences and insights from several years of efforts to meet the challenge of this new paradigm.



 

http://pubs.acs.org/toc/crtoec/22/2


0 Kudos
tfujimoto
Contributor

Orally Bioavailable IAP Antagonsits / Genentech

To generate new scaffolds that could potentially displace the dipeptide valine-proline motif, the software program CAVEAT was utilized. CAVEAT databases of minimized compounds from commercially available small molecules were constructed and searched. Genentech's chemists selected an azabicyclooctane as a synthetically accessible, conformationally constricted unique template. The synthetic strategy of azabicyclooctanes 4, and 5 is noteworthy. On the basis of Corey lactone's synthesis, treatment of gamma, delta-unsaturated amine 2 with iodine gave a bicyclic compound 3 through an iodonium intermediate.  Azides 6 and 7 from iodine 3 were separable on silica gel, and yield of each isomer was about 30%. Hydrogenation of the azide 7 provided the amine 5. In this scheme, gram scale synthesis of azabicyclo-intermediates 4 and 5 can be achieved. I think this template is an useful substructure as medicinal chemistry. The optimized compound 14b had 10-15-hold more potency than a flexible referred compound 15b, thus conformational constriction worked.

http://pubs.acs.org/doi/pdf/10.1021/jm801450c



0 Kudos
tfujimoto
Contributor

Naphthalene Based SSRIs, Part 1 / Pfizer

Sertraline, paroxetine, and fluoxetine are representative approved SSRIs. This paper shows lead generation of synthetic accessible naphthalene-baesd SSRIs from litoxetine. IC50 of SRI, NRI, and DRI, and Ki of IKr of synthetic compounds are disclosed. Interestingly, compounds 20 and 22 were triple reuptake inhibiting profile. These SAR is probably applied for design of various reuptake inhibitors.
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6TF9-4VNH3T1-6-1&_cdi=5221&_user=2645672&_o...



0 Kudos
tfujimoto
Contributor

Dual Acting 5-HT1R Antagonists and SSRIs, Part II / GSK

SB-744185 shows 5-HT1A/1B/1D antagonistic activity and SSRI, but potent hERG inhibitor. This report describes lead optimization to reduce hERG inhibition and balance multiple potency. Optimized strategies are a shuffle of benzoxazinones, change a length of a linker, and methylation of piperazine.
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6TF9-4VNH3T1-8-1&_cdi=5221&_user=2645672&_o...



0 Kudos
tfujimoto
Contributor

Selective 5-HT2cR Agonists: Hit-to-Lead Optimization / Pfizer

To discover a lead of potent 5-HT2cR agonist with good selectivity of 5-HT2A and 2B, hit-to-lead optimization was investigated. The key drug design is breaking ring of dihydrobenzofuran and ring-reconstruction of sulfonamide. A representative compound 3v shows good 5-HT2c potency and selectivity against 5-HT2A, 2B, and other off-targets, but moderate inhibiton of CYP2D6.
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6TF9-4VNKGSD-B-3&_cdi=5221&_user=2645672&_o...

 
0 Kudos
tfujimoto
Contributor

Oxadiazole-Diarylpyrazole as CB1R Ligands / Green Cross Co.

Isosteric replacement of hydrazide of rimonabant with oxadiazole was investigated.

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6TF9-4VNKGSD-4-1&_cdi=5221&_user=2645672&_o...



0 Kudos
tfujimoto
Contributor

Potent Orally Active CETP Inhibitor / J&J

Pharmacia's CETP inhibitor, compound 13 has highly potent, but modest oral exposure and in vivo efficacy. Such poor PK might result from the quite flexibility (12 rotatable bonds) of this compound. Hence, J&J's chemists designed conformationally constrained compounds to improve PK profile. Designed compound 13B displayed acceptable potency (400 nM) as a new scaffold. Lead optimization gave compound 12, which showed good potency (45 nM), and acceptable PK (rats: 31%, dogs:5%, monkeys: 27%). The low distribution of compound 12 may be favorable because CETP is present in plasma. This compound was orally efficacious in vivo. Notable synthetic strategies are 1) palladium-catalyzed acylation of acylchloride with organo-stannane; 2) a copper mediated intramolecular amination of Nosylamine by Fukuyama's method; and 3) N-alkylation with 1,1,1-trifluoro-2,3-epoxypropane and Yb(OTf)3.

http://pubs.acs.org/doi/pdf/10.1021/jm801319d


0 Kudos
tfujimoto
Contributor

Hybrid Design of MK-7009 with α-Ketoamide Macrocyclic Hepatitis C Virus NS3/4A Inhibitors / Merck

Currently, there are two types of NS3/4A protease inhibitors: (i) alpha-ketoamide serine-trap covalent modifier type and (ii) non-covalent reversible marcocyclic inhibitors. This paper disclosed MK-7009 currently in Phase-II. Furthermore, Merck's chemists designed the hybrid series of molecules designed by the combination of macrocycle portion of MK-7009 and the P1-P1' alpha-ketoamide warhead  of VX-950. The resulting compound 8b improved potency, but the PK profile was worse than VX-950.
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6TF9-4VPD6KH-3-1&_cdi=5221&_user=2645672&_o...



0 Kudos
tfujimoto
Contributor

Alkoxy-5-Phenoxy-N-thiazolyl Benzamides as GK Activators / Banyu

The starting lead 2a has an aniline structure, which sometimes exert the potential risk for mutagenecity. This report showed removing this aniline, and improved the potency based on crystal structure analysis. The optimized compound 27e exhibited a glucose-lowering effect after 10 mg / kg oral administration. The structure is similar to the previous reported compound by AstraZeneca.

http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6TF8-4VPD6KB-2-1&_cdi=5220&_user=2645672&_o...




0 Kudos